{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:09:24Z","timestamp":1792631364218,"version":"4.5.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To evaluate the early real-world clinical outcomes regarding the safety and efficacy after administration of a ranibizumab biosimilar (Ranieyes).\n                    <jats:bold>Methods:<\/jats:bold>\n                    This multicenter retrospective uncontrolled observational study incorporated data from 7 centers in India. All patients were treated with at least 1 intravitreal injection of 0.5 mg of ranibizumab biosimilar between July 2022 and July 2023 for various indications.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 474 ranibizumab biosimilar injections were given in 268 eyes of 254 patients. Indications were diabetic macular edema (DME) (n = 112), macular neovascularization (MNV) (n = 92), retinal vein occlusion (RVO) (n = 54), cystoid macular edema (n = 4), and proliferative diabetic retinopathy with vitreous hemorrhage (n = 6). The mean logMAR BCVA (\u00b1SD) improved significantly from baseline to the last follow-up as follows: DME cases, from 0.77 \u00b1 0.37 (Snellen equivalent, 6\/36) to 0.43 \u00b1 0.25 (6\/15) (\n                    <jats:italic>z<\/jats:italic>\n                    = \u22128.0;\n                    <jats:italic>r<\/jats:italic>\n                    = \u22120.8); MNV cases, from 0.95 \u00b1 0.53 (6\/60) to 0.59 \u00b1 0.42 (6\/24) (\n                    <jats:italic>z<\/jats:italic>\n                    = \u22127.1;\n                    <jats:italic>r<\/jats:italic>\n                    = \u22120.8); RVO cases, from 0.83 \u00b1 0.40 (6\/45) to 0.44 \u00b1 0.32 (6\/15) (\n                    <jats:italic>z<\/jats:italic>\n                    = \u22125.5;\n                    <jats:italic>r<\/jats:italic>\n                    = \u22120.8) (all\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). All groups also had a significant improvement in the central subfield thickness (all\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). No site reported drug-related adverse events (eg, inflammation, vasculitis, systemic adverse effects).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The preliminary real-world data from this limited early series suggest that Ranieyes has clinical efficacy and is safe as a ranibizumab biosimilar across the approved indications.\n                  <\/jats:p>","DOI":"10.1177\/24741264251322213","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:40:35Z","timestamp":1740710435000},"page":"330-335","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-9791","authenticated-orcid":false,"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[{"name":"Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Madhavi Netralaya, Ara, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[{"name":"Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, USA"},{"name":"Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemantini","family":"Ayachit","sequence":"additional","affiliation":[{"name":"Dr. P.S. Hardia Eye Hospital and Research Center, Rau, Indore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitaranjan","family":"Mishra","sequence":"additional","affiliation":[{"name":"Trilochan Netralaya, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[{"name":"Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdulal","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Disha Eye Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-1631","authenticated-orcid":false,"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[{"name":"Retina Vitreous Associates of Florida, St. Petersburg, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[{"name":"Banker\u2019s Retina Clinic and Laser Centre, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikulaa","family":"Parachuri","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Akshara Eye Hospital, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Tel Aviv Medical, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[{"name":"University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Wakabayashi Eye Clinic, Nonoichi, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[{"name":"Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1866_19"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003626"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.11.017"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0722-6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2176218"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0636-3"},{"key":"e_1_3_2_9_2","article-title":"International Retina Biosimilar Study Group (Inter-BIOS Group). Anti-VEGF Biosimilars for Retinal Diseases Survey 2023-India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)","author":"Sharma A","unstructured":"Sharma A, Kaiser PK, Tadayoni R, et al. International Retina Biosimilar Study Group (Inter-BIOS Group). Anti-VEGF Biosimilars for Retinal Diseases Survey 2023-India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (Lond). 2024 Dec;38(17):3392-3395. doi:10.1038\/s41433-024-03284-x","journal-title":"Eye (Lond)"},{"key":"e_1_3_2_10_2","unstructured":"Lupin receives CDSCO committee approval for marketing ranibizumab. Accessed September 21 2023. http:\/\/www.pharmabiz.com\/NewsDetails.aspx?aid=139853&sid=1"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_2118_21"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02246-5"},{"key":"e_1_3_2_13_2","unstructured":"Biocon biologics receives European Commission approval for YESAFILI\u00ae biosimilar aflibercept. September 20 2023. Accessed September 22 2023. https:\/\/www.biocon.com\/biocon-biologics-receives-european-commission-approval-for-yesafili-biosimilar-aflibercept\/"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101358"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03220-z"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000488602"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-00228-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0434-y"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0853-9"},{"key":"e_1_3_2_20_2","unstructured":"Mullard A. FDA rejects first DARPin. July 7 2020. Accessed September 25 2024. https:\/\/www.nature.com\/articles\/d41573-020-00127-8"},{"key":"e_1_3_2_21_2","unstructured":"Hutton D. ASRS reports six cases of occlusive retinal vasculitis linked to pegcetacoplan injection. July 19 2023. Accessed September 9 2023. https:\/\/www.ophthalmologytimes.com\/view\/asrs-reports-six-cases-of-occlusive-retinal-vasculitis-linked-to-pegcetacoplan-injection"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0745-z"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231202080"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251322213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251322213","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251322213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:23Z","timestamp":1790695463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251322213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/24741264251322213"],"URL":"https:\/\/doi.org\/10.1177\/24741264251322213","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}